MHRA Issues Revised Warning on GLP-1 Medications
On 29 January 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced updated guidance for healthcare professionals and patients regarding a small risk associated with Glucagon-Like Peptide-1 (GLP-1) receptor agonists, particularly concerning severe acute pancreatitis. While GLP-1 medications, widely used for managing Type 2 diabetes and aiding weight loss, are regarded as safe, this warning highlights the importance of recognizing symptoms of potential complications.
Understanding the Risk of Acute Pancreatitis
Acute pancreatitis is now acknowledged as a rare, but possible side effect of GLP-1 therapy. Patient symptoms may include severe, persistent abdominal pain that can radiate to the back, often accompanied by nausea and vomiting. Clinicians and patients are urged to remain vigilant in monitoring for these initial signs.
Prevalence and Usage of GLP-1s
GLP-1 medications, such as semaglutide (brand names Wegovy and Ozempic) and tirzepatide (Mounjaro), are commonly prescribed for Type 2 diabetes management, cardiovascular risk reduction, and weight management among individuals with a BMI of 27 kg/m² or higher. According to a study conducted by University College London, an estimated 1.6 million adults across England, Wales, and Scotland utilized GLP-1s between early 2024 and early 2025 in their weight-loss efforts.
Safety Assurance from MHRA
Alison Cave, the MHRA’s Chief Safety Officer, reassured that patient safety remains the agency’s highest concern, emphasizing that GLP-1s are generally safe for most patients when administered according to established guidelines. Although the likelihood of experiencing severe side effects is minimal, awareness of the symptoms associated with pancreatitis is crucial.
Patients or caregivers who observe symptoms like severe stomach pain are advised to consult a healthcare professional promptly and report such instances through the MHRA’s Yellow Card scheme.
Ongoing Research and Future Insights
The MHRA is collaborating with Genomics England to investigate genetic factors that may influence the risk of acute pancreatitis among patients using GLP-1s. This initiative, named the Yellow Card Biobank, aims to enhance understanding and prediction of adverse reactions to facilitate safer medication prescriptions in the future.
Access to Further Information
For comprehensive guidance on the potential side effects and appropriate use of GLP-1 medications, further details can be found on the official MHRA website.
Source: official statements, news agencies, and public reports.
https://www.gov.uk/government/news/mhra-updates-guidance-for-glp-1-prescribers-and-patients
